Full Text View
Tabular View
Study Results
Related Studies
An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) (GLOW)
This study has been terminated.
Study NCT01578785   Information provided by Teva Pharmaceutical Industries

First Received on March 13, 2012.   Last Updated on February 19, 2014   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
More general conditions related to this trial
Interventions listed in this trial
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Sponsors listed in this trial